Fortress Biotech, Inc. - Dec 31, 2024 Form SCHEDULE 13D/A Schedule Report for Avenue Therapeutics, Inc. (ATXI)

Filing Manager: Fortress Biotech, Inc.
Reporting Manager: Fortress Biotech, Inc.
Security: Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value
Symbol: ATXI
Shares outstanding: 2.14M shares
Disclosed Ownership: 295K shares
Ownership: 13.8%
Form type: SCHEDULE 13D/A
Date filed: 1/3/2025, 05:50 PM
Date of event: Dec 31, 2024
Next filing: Apr 2, 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Fortress Biotech, Inc.	13.8%	295K	295K	0	/s/ Lindsay A. Rosenwald	Lindsay A. Rosenwald, M.D. / Chairman, President and Chief Executive Officer	0001429260